We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders
News

Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders

Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders
News

Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncolytics Biotech Inc. has announced that it has been granted its 35th U.S. Patent, No. 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."

The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.
Advertisement